RGEN
$65.66
Repligen Cp
$.27
.41%
RGEN
Earnings Whisper ®
N/A
4th Quarter December 2018
Consensus:  $0.21
Revenue:  N/A
Thursday
Jan 31
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, November 1, 2018

What do you expect when RGEN reports earnings?
Beat
Meet
Miss

Where is RGEN's stock price going from here?
Up
Flat
Down
Stock chart of RGEN
Analysts
Summary of analysts' recommendations for RGEN
Score
Grade
Pivots
Resistance
$67.84
$67.25
$66.32

$65.73

Support
$64.80
$64.21
$63.28
Tweet
Growth
Description
Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS? series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development.
Peers
BiogenGilead SciencesAmgenBluebird BioNeurocrine BiosciencesSeattle GeneticsQiagen N.V.BioCryst PharmaceuticalsSangamo TherapeuticsBio-Techne